Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Philogen SpA ( (IT:PHIL) ) has issued an announcement.
Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 790 shares at an average price of Euro 22.50 per share, totaling Euro 17,775.00. Since the program’s inception, the company has acquired 14,742 shares, representing 0.0363% of its share capital, which may impact its market positioning and shareholder value.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company focused on the research and development of pharmaceutical products, particularly targeted anti-cancer drugs. The company utilizes proprietary technologies to develop ligands that selectively deliver therapeutic agents to tumor masses, aiming to treat diseases with high mortality rates. Philogen’s approach, called vascular targeting, is primarily used for cancer treatment but is also applicable to other diseases, such as chronic inflammatory conditions.
Average Trading Volume: 9,446
Technical Sentiment Signal: Buy
Current Market Cap: €658M
See more insights into PHIL stock on TipRanks’ Stock Analysis page.